Literature DB >> 15180441

A population-based study on the incidence of inflammatory bowel disease in Oviedo (Northern Spain).

L Rodrigo1, S Riestra, P Niño, V Cadahía, R Tojo, D Fuentes, M Moreno, E González Ballina, E Fernández.   

Abstract

OBJECTIVE: to assess the incidence of inflammatory bowel disease in Oviedo (Northern Spain), and to describe the clinical features of new patients. PATIENTS AND METHODS: a prospective population-based study was made at the Health Area IV, Principality of Asturias (Oviedo, 312,324 inhabitants). All new diagnosed patients with inflammatory bowel disease were registered over a 2-year period.
RESULTS: a total of 85 patients were included, 47 of these with ulcerative colitis (UC), 37 with Crohńs disease (CD), and 1 with undetermined colitis. The overall adjusted incidence rate of UC and CD per 105 inhabitants between 15-64 years was 9.1 (95% CI: 5-13.1) and 7.5 (95% CI: 3.8-11.2), respectively. The global male/female ratio was 0.9, without significant differences between both diseases. CD patients were younger than those with UC (33 +/- 15 years vs 45 +/- 20 years; p < 0.05). Mostly, CD patients were diagnosed at an age younger than 35 years (65%), while UC patients were diagnosed at an age between 25 and 64 years (81%). Disease extension in UC was proctitis in 11%, left-side colitis in 53% and extensive colitis in 36%. With respect to CD, the ileo-colonic form predominated (49%), followed by the ileal (40%) and colonic (11%) forms; an inflammatory, stenotic and fistulous pattern was seen in 54, 22 and 24% of patients, respectively.
CONCLUSIONS: in our area, the incidence of CD is similar to that in other Northern European countries, while UC has a lower incidence. CD mainly affects young people, while UC predominates in middle-aged patients. At diagnosis, UC is predominantly localized, the ileo-colonic form and an inflammatory pattern being most frequent in CD patients.

Entities:  

Mesh:

Year:  2004        PMID: 15180441     DOI: 10.4321/s1130-01082004000500002

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  6 in total

1.  The role of polymorphisms of genes CXCL12/CXCR4 and MIF in the risk development IBD the Polish population.

Authors:  Jerzy Mrowicki; Karolina Przybylowska-Sygut; Lukasz Dziki; Andrzej Sygut; Jan Chojnacki; Adam Dziki; Ireneusz Majsterek
Journal:  Mol Biol Rep       Date:  2014-04-01       Impact factor: 2.316

Review 2.  Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing?

Authors:  Cristina Saro Gismera; Beatriz Sicilia Aladrén
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

3.  Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study).

Authors:  Ignacio Marín-Jiménez; Cristina Saro; Verónica Díaz; Manuel Barreiro-de Acosta; María Gómez-García; Ana Gutiérrez Casbas
Journal:  Drugs Context       Date:  2018-03-06

4.  EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.

Authors:  María Chaparro; Manuel Barreiro-de Acosta; José Manuel Benítez; José Luis Cabriada; María José Casanova; Daniel Ceballos; María Esteve; Hipólito Fernández; Daniel Ginard; Fernando Gomollón; Rufo Lorente; Pilar Nos; Sabino Riestra; Montserrat Rivero; Pilar Robledo; Cristina Rodríguez; Beatriz Sicilia; Emilio Torrella; Ana Garre; Esther García-Esquinas; Fernando Rodríguez-Artalejo; Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2019-05-21       Impact factor: 4.409

Review 5.  Current global trends in the incidence of pediatric-onset inflammatory bowel disease.

Authors:  Josef Sýkora; Renáta Pomahačová; Marcela Kreslová; Dominika Cvalínová; Přemysl Štych; Jan Schwarz
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

6.  Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts.

Authors:  Tom Thomas; Joht Singh Chandan; Venice Sze Wai Li; Cheuk Yin Lai; Whitney Tang; Neeraj Bhala; Gilaad G Kaplan; Siew C Ng; Subrata Ghosh
Journal:  PLoS One       Date:  2019-09-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.